Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients

INTRODUCTION: The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice. METHODS: This post-marketing sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Namba, Kenichi, Kaburaki, Toshikatsu, Tsuruga, Hidekazu, Ogawa, Yohei, Iwashita, Eri, Goto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114192/
https://www.ncbi.nlm.nih.gov/pubmed/35305254
http://dx.doi.org/10.1007/s40123-022-00493-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114192/
https://www.ncbi.nlm.nih.gov/pubmed/35305254
http://dx.doi.org/10.1007/s40123-022-00493-z

Ejemplares similares